科研成果详情

题名CalliSpheres (R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study
作者
发表日期2019-02
发表期刊CLINICAL & TRANSLATIONAL ONCOLOGY   影响因子和分区
语种英语
原始文献类型Article
关键词Drug-eluting beads transarterial chemoembolization (DEB-TACE) Efficacy Safety Previous cTACE treatment Liver cancer
其他关键词UNRESECTABLE HEPATOCELLULAR-CARCINOMA ; EFFICACY ; CTACE
摘要PurposeTo assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.Methods367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.ResultsThere was no difference in complete response (CR) (P=0.671) and objective response rate (ORR) (P=0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P=0.899) was found. As to liver function, most liver function indexes were deteriorative at 1week after DEB-TACE operation, but returned to baseline at 1-3months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3month post-DEB-TACE (P=0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P=0.005), while no difference of other adverse events was found during and 1month post-DEB-TACE treatment among three groups.ConclusionDEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.
资助项目National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371658]; Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LZ18H180001]
出版者SPRINGER INT PUBL AG
出版地CHAM
ISSN1699-048X
EISSN1699-3055
卷号21期号:2页码:167-177
DOI10.1007/s12094-018-1902-8
页数11
WOS类目Oncology
WOS研究方向Oncology
WOS记录号WOS:000457562500006
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
PubMed ID30003530
SCOPUSEID2-s2.0-85049774881
通讯作者地址[Shao G.-L.]Department of Intervention,Zhejiang Cancer Hospital,No. 1 Banshan East Road,Hangzhou,310022,China
Scopus学科分类Oncology;Cancer Research
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/20716
专题其他_附属第三医院(瑞安市人民医院)
附属第一医院
其他_附属第五医院(丽水市中心医院)
通讯作者Shao G.-L.
作者单位
1.Interventional Radiology Department,The First Affiliated Hospital,Zhejiang University,No. 79 Qingchun Road,Hangzhou,310006,China;
2.Department of Radiology,Hangzhou Cancer Hospital,No. 34 Yan Guan lane,Hangzhou,China;
3.Department of Liver Oncology,Ningbo No. 2 Hospital,No. 41 Xibei Road,Ningbo,315010,China;
4.Department of Hepatobiliary Surgery,Ningbo Medical Center Lihuili Easter Hospital,No. 1111 Jiangnan Road,Ningbo,315000,China;
5.Department of Radiology,Beilun District People’s Hospital of Ningbo,No. 1288 Lushang East Road,Ningbo,315826,China;
6.Department of Intervention,Ruian People’s Hospital,The Third Affiliated Hospital of Wenzhou Medical University,No. 108 Wansong Road,Ruian,325200,China;
7.Department of Radiology,The First Affiliated Hospital of Zhejiang Chinese Medical University,Zhejiang Hospital of TCM,No. 54 Youdian Road,Hangzhou,310006,China;
8.Department of Radiology,Xixi Hospital of Hangzhou,Hangzhou 6th People’s Hospital,Hengbu Street 2,Hangzhou,310023,China;
9.Department of Intervention,Zhejiang Provincial People’s Hospital,People’s Hospital of Hangzhou Medical College,No. 158 Shangtang Road,Hangzhou,310000,China;
10.Department of Radiology,Lishui Central Hospital,Lishui Hospital of Zhejiang University,The Fifth Affiliated Hospital of Wenzhou Medical University,No. 289 Kuocang Road,Lishui,323000,China;
11.Department of Intervention,Jiaxing Second Hospital,No. 1518 Huangcheng North Road,Jiaxing,314000,China;
12.Division of Hepatobiliary and Pancreatic Surgery,Hepatobiliary and Pancreatic Interventional Treatment Center,The First Affiliated Hospital,Zhejiang University,No. 79 Qingchun Road,Hangzhou,310006,China;
13.Interventional Center,Xinchang People’s Hospital,No. 117 Gushan Road,Xinchang,312500,China;
14.Department of Intervention,Jinhua Municipal Central Hospital,Jinhua Hospital of Zhejiang University,No. 365 Renmin East Road,Jinhua,321000,China;
15.Department of Radiology,Shulan (Hangzhou) Hospital,No. 848 Dongxin Road,Hangzhou,310026,China;
16.Department of Vascular and Interventional Radiology,The Affiliated Hospital of Medical School of Ningbo University,No. 247 Renmin Road,Ningbo,315020,China;
17.Division of Digestive Endoscopy,Yueqing City People’s Hospital,No. 338 Qingyuan Road,Yueqing,325600,China;
18.Department of Hepatobiliary Surgery,Quzhou People’s Hospital,No. 2 Zhongloudi,Quzhou,324000,China;
19.Department of Intervention,The First Provincial Wenzhou Hospital of Zhejiang,The First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Lane,Wenzhou,325099,China;
20.Department of Radiology,Taizhou Hospital of Zhejiang Province,No. 150 Ximen Street,Linhai,317000,China;
21.Department of Intervention,Jiaxing First Hospital,No. 1882 Zhonghuan South Road,Jiaxing,314001,China;
22.Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,No. 3 Qingchun East Road,Hangzhou,310016,China;
23.Department of Intervention,Zhejiang Cancer Hospital,No. 1 Banshan East Road,Hangzhou,310022,China;
24.Department of Intervention,Dongyang People’s Hospital,No. 60 Wuning West Road,Dongyang,322100,China
推荐引用方式
GB/T 7714
Zhang X.,Zhou J.,Zhu D.-D.,et al. CalliSpheres (R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study[J]. CLINICAL & TRANSLATIONAL ONCOLOGY,2019,21(2):167-177.
APA Zhang X.., Zhou J.., Zhu D.-D.., Huang J.., Sun J.-H.., ... & Shao G.-L.. (2019). CalliSpheres (R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. CLINICAL & TRANSLATIONAL ONCOLOGY, 21(2), 167-177.
MLA Zhang X.,et al."CalliSpheres (R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study".CLINICAL & TRANSLATIONAL ONCOLOGY 21.2(2019):167-177.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Zhang X.]的文章
[Zhou J.]的文章
[Zhu D.-D.]的文章
百度学术
百度学术中相似的文章
[Zhang X.]的文章
[Zhou J.]的文章
[Zhu D.-D.]的文章
必应学术
必应学术中相似的文章
[Zhang X.]的文章
[Zhou J.]的文章
[Zhu D.-D.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。